Merck Increases Quarterly Dividend

  Merck Increases Quarterly Dividend

Business Wire

WHITEHOUSE STATION, N.J. -- November 27, 2012

Merck, known as MSD outside the United States and Canada, today announced that
the Board of Directors has increased the company's quarterly dividend to $0.43
per outstanding share of the company's common stock, up $0.01 from $0.42 per
outstanding share paid last quarter. Payment will be made on Jan. 8, 2013, to
shareholders of record at the close of business on Dec. 17, 2012.

“This increase in our dividend reflects our optimism about the future of our
business and our commitment to providing value to our shareholders," said
Kenneth C. Frazier, chairman and chief executive officer of Merck.

Merck last announced a dividend increase in November 2011, when the Board
raised the dividend from $0.38 to $0.42 per common share.

About Merck

Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit and
connect with us on Twitter, Facebook and YouTube.

Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. Such statements may include, but are not limited to,
statements about the benefits of the merger between Merck and Schering-Plough,
including future financial and operating results, the combined company’s
plans, objectives, expectations and intentions and other statements that are
not historical facts. Such statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. Actual results may differ from those set forth in the
forward-looking statements.

The following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the possibility that all of
the expected synergies from the merger of Merck and Schering-Plough will not
be realized, or will not be realized within the expected time period; the
impact of pharmaceutical industry regulation and health care legislation in
the United States and internationally; Merck’s ability to accurately predict
future market conditions; dependence on the effectiveness of Merck’s patents
and other protections for innovative products; and the exposure to litigation
and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2011
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site


Ron Rogers, 908-423-6449
Carol Ferguson, 908-423-4465
Justin Holko, 908-423-5088
Press spacebar to pause and continue. Press esc to stop.